Conor Fearon

Cullinane et al. identify three subtypes of progressive supranuclear palsy with different progression patterns and show that sex, genetic variation, and co-pathology influence tau distribution and clinical phenotype. shorturl.at/1cZcy

World Parkinson’s Day may have taken place over the weekend (April 11th), but raising awareness doesn’t stop there 💙 This important day is a reminder of the strength, resilience, and community behind those living with neurological conditions🧠 #WorldParkinsonsDay

We are very proud of this achievement! Congratulations to @LucaMarsili1, @AMahajanMD, @AlbertoEspay, and the other faculty and co-authors of this award-winning manuscript! 🎉🧠

Genetic differentials of Rapid onset Dystonia Parkinsonism: ATP1A3, SLC19A3 (BTBGD), PRKRA @FearonConor @MDJ_Journal #neurotwitter doi.org/10.1002/mds.70…

Did you know AD pathology also impacts PD and related disorders? This review underscores the impact of aβ and tau co-pathology on clinical progression and heterogeneity in PD and atypical parkinsonism, emphasizing the value of biomarker approaches. 301.tv/HYSwt

Several MDS rating scales now have official versions within REDCap, thanks to efforts by the Electronic COA Committee to promote compliance and uniformity in clinical research. @MDJ_Journal …mentdisorders.onlinelibrary.wiley.com/doi/10.1002/md…

The University of Cincinnati Movement disorders fellowship is well represented at the #PASCongress! Super proud.

Superb presentation on the future of #ataxia treatment by @neurosrq today at #PASCongress @movedisorder

Dementia with Lewy bodies: a practical guide to clinical diagnosis and management pn.bmj.com/content/26/1/4

Our group just published the First Saudi data on fatigue in Parkinson’s disease: • 61% had significant fatigue (FSS ≥4) • Fatigue linked to non-motor symptoms • Higher risk with low physical activity and low water intake link.springer.com/article/10.100… #ParkinsonsDisease #Fatigue

Recurrent “delirium”, normal scans, fluctuating cognition - sound familiar? Our recent review shows why dementia with Lewy bodies is often hiding in plain sight, and how to recognise it early in clinic and on the ward. 🔓 Open access: pn.bmj.com/content/26/1/4 #Neurology #OpenAccess #FOAMed

🧠𝗗𝗼 𝘆𝗼𝘂 𝗹𝗶𝘃𝗲 𝘄𝗶𝘁𝗵 𝗣𝗮𝗿𝗸𝗶𝗻𝘀𝗼𝗻’𝘀 𝗱𝗶𝘀𝗲𝗮𝘀𝗲? We want to hear your views on technology! 💬 💡 Your experience can shape future tools and research 👉 tinyurl.com/3pt73cf5 #ParkinsonsDisease #PDresearch #ParkinsonsAwareness

After rewatching Home Alone, I couldn’t stop wondering: how plausible is the oversleep that leaves Kevin behind? So I wrote a tiny paper and ran the numbers. Merry Christmas! 🎄

@ec_bayram 😂

in my amateur coding adventure, today i met claude. let's see what you got young fella 🤓

Foslevodopa infusion in the real world has shown promise for Parkinson's, however we must pay attention to any emergent neuropsychiatric symptoms. Continuous subcutaneous infusion refers to medication delivered under the skin at a steady rate to smooth out motor fluctuations. This research letter provides important insights into safety signals that may emerge when folks start and adjust this therapy at home. Maeve Bradley and colleagues describe in Movement Disorders Clinical Practice their extended real world experience w/ foslevodopa foscarbidopa using an outpatient titration protocol. Key Points: - Outpatient initiation was feasible, however dose optimization still required several weeks and infusion rates increased by an average of 35% from baseline. -Neuropsychiatric complications were more frequent w/ hallucinations emerging in 21 percent of patients and frequently appearing weeks after initiation. - Discontinuation rates were similar to inpatient programs, however reasons differed and included neuropsychiatric symptoms, infusion site issues and lack of effectiveness. My take: We will need to provide guidance on when to employ pump therapies in Parkinson's and what to do if neuropsychiatric symptoms emerge. Real-world data is really important to this effort. Here are 5 points that resonated w/ me: 1- Expect individualized dosing because stable infusion rates usually take weeks to achieve and will require close follow up. 2- Watch for delayed hallucinations because these symptoms may appear long after the first few days of treatment and require rapid adjustment. 3- Understand the role of past psychosis since a history of hallucinations may increase risk, however does not perfectly predict who will struggle. 4- Rely on your care team because trained nurses visiting at home can safely guide adjustments and keep therapy on track. 5- Recognize when to stop because some folks will discontinue due to neuropsychiatric issues or skin reactions, and switching therapies may be the best option for some folks. …mentdisorders.onlinelibrary.wiley.com/doi/10.1002/md… @ParkinsonDotOrg @FixelInstitute @PdAvengers @ACPIMPhysicians @movedisorder

It was wonderful having you in Dublin. A masterclass in itself! Your grand rounds performance was a tour de force. We’ll have to find even more complex cases next year!

Kicking off the 25th annual PD masterclass. Great to see a full house for an excellent line up of national and international speakers 👏🏻

@AlbertoEspay The difference is that that little patch of rain stays over Dublin all year round!! Have a safe flight.

Another reason to fly to Dublin today: sharing similarly rainy conditions with Cincinnati. That’s a connection! ⁦🙏🏻@FearonConor⁩?

Our annual Movement Disorder Masterclass is fast approaching 🧠 This year's guest speakers include Dr Alberto Espay, Dr Anhar Hassan and Patient advocate and fashion editor Ms Annmarie O'Connor.  Spaces are filling fast, so don’t wait! lnkd.in/eQFrZtSS